ArticleScientific reports2025
Left ventricular septal convexity in differentiating hypertrophic cardiomyopathy from hypertensive heart disease - a cardiac magnetic resonance study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Coexistence of Hypertrophic Cardiomyopathy and Arterial Hypertension: Current Insights and Future Directions.Diseases (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Both hypertrophic cardiomyopathy (HCM) and hypertensive heart disease (HHD) are characterized by left ventricular hypertrophy. Distinguishing HCM from HHD is a common clinical problem, particularly in subjects with moderate left ventricular maximal wall thickness (LVMWT) < 18 mm. Previously, we showed that cardiac magnetic resonance (CMR)-derived septal convexity (SC) into the left ventricle is increased in subjects with HCM-causing mutations with and without LVH. Our objective now was to determine whether CMR-derived SC differentiates HCM from HHD. We measured the maximal distance between the LV septal endocardial border and a line connecting the proximal and distal septal mid-wall points in 4-chamber images, in subjects with hypertension and LVH (n = 29), in subjects with HCM (n = 49), and in healthy controls (n = 20). Here, we show significantly increased SC in subjects with HCM compared to subjects with HHD both in non-indexed and in BSA-indexed measurements. Cutoff SC values of 7.9 mm and 3.7 mm/m2 in all HCM patients and SC values of 7.9 mm and 3.8 mm/m2 in HCM patients with LVMWT < 18 mm differentiated between HCM and HHD with good sensitivity and excellent specificity: SC cutoff value of 7.9 mm had a sensitivity of 77% and a specificity of 90% in all HCM patients, and 67% and 90% in HCM patients with LVMWT < 18 mm, respectively. Our study shows that measuring CMR-derived septal convexity is straightforward and enhances diagnostic performance, providing a novel technique to distinguish between HCM caused by sarcomere mutations and hypertension-induced LVH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.